Brachytherapy can be used as a single therapy (monotherapy) in patients with low-risk cancers and select individuals with low-volume intermediate risk cancers. Intermediate-risk prostate cancers can be treated by a combination of brachytherapy and EBRT +/- 4-6 months of neoadjuvant, concomitant/adj...
Brachytherapy can be used as a single therapy (monotherapy) in patients with low-risk cancers and select individuals with low-volume intermediate risk cancers. Intermediate-risk prostate cancers can be treated by a combination of brachytherapy and EBRT +/- 4-6 months of neoadjuvant, concomitant/adj...
Patients selection flow chart Full size image Table 1 Baseline Characteristics of Patients with Negative mpMRI. Full size table Univariate logistic regression analysis indicated that older age, higher PSA levels, lower f/tPSA ratio, smaller prostate volume, and higher PSAD were all significantly assoc...
Genome Medicine volume 15, Article number: 82 (2023) Cite this article 3292 Accesses 4 Citations 2 Altmetric Metrics details Abstract Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context...
et al. Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population. Eur. Urol. 70(1), 6–8. https://doi.org/10.1016/j.eururo.2016.01.027 (2016). Article CAS PubMed Google Scholar Helfand, B. T., Catalona...
Analysis of factors that predict PCa on TTSB In the multivariate analysis, the factors that predicted PCa on TTSB were high age (odds ratio [OR]: 3.99, 95% confidence interval [CI]: 1.55–10.3), high PSA density (OR: 6.89, 95% CI: 2.62–18.2), low prostate volume (OR: 0.24, 95...
www.cdc.gov/pcd/issues/2010/jul/09_0167.htm • Centers for Disease Control and Prevention VOLUME 7: NO. 4 JULY 2010 Table 3. Associations Between PSA Testing and Various Characteristics Among Men Aged 76 Years or Older With No History of Prostate Cancer, BRFSS...
Prostate biopsies can miss cancer. The inherent flaw in a biopsy to search for cancer is a relatively high false negative rate because the biopsies can only sample a very small percentage of the prostate volume. Even a targeted MRI/Ultrasound fusion biopsy can miss cancerous cells. My prognosis...
Brachytherapy can be used as a single therapy (monotherapy) in patients with low-risk cancers and select individuals with low-volume intermediate risk cancers. Intermediate-risk prostate cancers can be treated by a combination of brachytherapy and EBRT +/- 4-6 months of neoadjuvant, concomitant/adj...
(DF) tumour samples from the TCGA dataset.E–GMettl1is highly expressed in mouse prostate tumours.Mettl1expression analysis inPten-KOmice at 3 and 6 months of age compared to wild-type mice (WT) at the same ages by western blot (E, F) and RT-qPCR (G). * in (E) indicates an ...